Viridian Posts $69.72/Share Q1 Loss, Deepening Cash Burn
VRDN sits 63% above its 52-week low of $13.18.
Summary
Viridian reported a Q1 loss of $69.72 per share, a stark figure that underscores the company's heavy cash consumption. This follows a $359 million capital raise in May and a recent FDA approval for Lumvoa, its thyroid eye disease drug. The loss highlights the gap between R&D spending and commercial revenue, which is just beginning with the Lumvoa launch. Investors will focus on the pace of the drug's uptake and whether the recent financing provides sufficient runway to reach breakeven.
At the time of this announcement, VRDN was trading at $21.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.3B. The 52-week trading range was $13.18 to $34.29. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.